Background: Monoclonal free light chains (FLCs) frequently cause rapidly progressive renal failure in patients with multiple myeloma. Immunoassays which provide quantitative measurement of FLCs in ...

In the phase 3, randomized CARTITUDE-4 trial involving patients with lenalidomide-refractory multiple myeloma who had received ... normal free light-chain ratio, and absence of clonal cells ...

However, amyloidosis in general is a systemic disease, so it can affect multiple ... for ruling out light chain amyloidosis. So those tests include two blood tests, one is kappa [and] lambda ...

Immunoglobulin light chain amyloidosis (AL) and multiple myeloma (MM) both share the overproduction of a clonal light chain (LC). However, while LCs in MM remain soluble in circulation, AL LCs misfold ...

with a focus on identifying a conformational fingerprint to differentiate amyloidogenic light chains from multiple myeloma light chains. The study's major contribution is the identification of a ...

However, recent evidence suggests that myeloma ... He had an IgG/ kappa monoclonal gammopathy of undetermined significance (MGUS) diagnosed in 2021 (M-spike of 0.38 g/dL on serum protein ...

which has revolutionized the treatment of multiple myeloma (70). The UPS has been implicated in the pathogenesis of autoimmune diseases. This association has shed light on the complex pathological ...

Multiple myeloma is a type of blood cancer that forms in plasma cells, white blood cells that produce infection-fighting antibodies. Multiple myeloma is not hereditary, meaning it is not passed ...

Saad Usmani, Chief of MSK's Myeloma Service, says there are far more treatment options for multiple myeloma today compared with just 20 years ago. Note: This story was originally published in 2022 and ...